Cargando…
Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway
The aim of the present study was to investigate the underlying mechanism of AS‐IV and CCN1 in PAH and to evaluate whether the protective effect of AS‐IV against PAH is associated with CCN1 and its related signalling pathway. In vivo, male SD rats were intraperitoneally injected with monocrotaline (M...
Autores principales: | Liu, Yu, Tang, Bai‐Lin, Lu, Mei‐Li, Wang, Hong‐Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983322/ https://www.ncbi.nlm.nih.gov/pubmed/36762748 http://dx.doi.org/10.1111/jcmm.17681 |
Ejemplares similares
-
Astragaloside IV blocks monocrotaline-induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling
por: Jin, Haifeng, et al.
Publicado: (2021) -
Astragaloside IV Stimulates Angiogenesis and Increases Nitric Oxide Accumulation via JAK2/STAT3 and ERK1/2 Pathway
por: Wang, Shi-Guang, et al.
Publicado: (2013) -
Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway
por: Xi, Jie, et al.
Publicado: (2023) -
Astragaloside IV attenuates inflammatory response mediated by NLRP‐3/calpain‐1 is involved in the development of pulmonary hypertension
por: Sun, Yang, et al.
Publicado: (2020) -
Astragaloside IV Attenuates Glutamate-Induced Neurotoxicity in PC12 Cells through Raf-MEK-ERK Pathway
por: Yue, Rongcai, et al.
Publicado: (2015)